Skip to main content

2018 NIH Alzheimer's Research Summit - Program and Agenda

N I H Alzheimer's Disease Research Summit 2018: Path to Treatment and Prevention. March 1-2 2018, Bethesda, MD.

The 2018 NIH Alzheimer's Disease Research Summit will be held March 1-2 at the Natcher Auditorium, NIH campus, in Bethesda, Maryland, hosted by the National Institute on Aging (NIA), part of the National Institutes of Health (NIH) at the U.S. Department of Health and Human Services. The Summit is supported by the NIH and by the private sector through generous gifts to the Foundation for the National Institutes of Health (FNIH).

Summit Registration

Participants can attend the NIH AD Summit in person or watch via live videocast.

View Meeting Agenda

Speakers' Biographies (to be posted soon).

Background: The NIH AD Research Summits are key strategic planning meetings tied to the implementation of the first goal of the National Plan to Address Alzheimer's: to treat and prevent Alzheimer's disease by 2025. They bring together a multi-stakeholder community including government, industry, academia, private foundations, and patient advocates to formulate an integrated, translational research agenda that will enable the development of effective therapies (disease modifying and palliative) across the disease continuum for the cognitive as well as neuropsychiatric symptoms of Alzheimer's disease.

The 2012 and 2015 AD Research Summits delivered recommendations that served as the basis for developing research implementation milestones detailing specific steps and success criteria for the NIH and other stakeholders towards the development of effective treatment and prevention for AD. The milestones span the entire AD research landscape including basic, translational, clinical and health services research and serve as the basis for the development of the NIH Alzheimer's Disease Bypass Budget.

Goal: The 2018 Summit will build on the foundation laid by the NIH AD Research Summits held in 2012 and 2015. It will feature progress towards achieving the AD research implementation milestones and to continue the development of an integrated multidisciplinary research agenda necessary to enable precision medicine for AD. Key to achieving this goal is the identification of: 1) resources/infrastructure and multi-stakeholder partnerships necessary to successfully implement this research agenda and 2) strategies to engage patients, caregivers, and citizens as direct partners in research.

Program Structure: The central programmatic themes of the 2018 Summit are: 1) understanding disease heterogeneity, 2) enhancing research rigor, reproducibility, and translatability and 3) enabling rapid translational learning through open science systems and incentives.

The Program agenda will be organized around seven sessions:

  1. Novel Mechanistic Insights into the Complex Biology and Heterogeneity of AD
  2. Enabling Precision Medicine for AD
  3. Translational Tools and Infrastructure to Enable Predictive Drug Development
  4. Emerging Therapeutics
  5. Understanding the Impact of the Environment to Advance Disease Prevention
  6. Advances in Disease Monitoring, Assessment and Care
  7. Building an Open Science Research Ecosystem to Accelerate AD Therapy Development

The program will begin with an overview of progress achieved to date, followed by three plenary lectures. Each of the seven sessions will feature up to four brief presentations followed by a moderated discussion that will include 6-9 panelists with diverse expertise. Collectively, the session speakers and panelists will highlight major advances and discuss key issues. The composition of speakers and panelists for each session will include representatives from academia, industry, federal agencies, private foundations and public advocacy groups working on Alzheimer's and other complex diseases.

Outcome: The general program will be followed by a writing session during which a select group of experts together with NIA/NIH staff and representatives from other U.S. AD funding agencies and NAPA Council members will discuss and help finalize the recommendations put forward by the Summit participants. These recommendations will inform research priorities and serve as the basis for updating and refining the NAPA research milestones for measuring progress towards the goal to prevent or treat AD by 2025.

AGENDA

DAY ONE

8:00am - 8:10am

  • Opening Remarks
    Francis Collins, Director, NIH

8:10am - 8:30am

  • Introduction to the Summit Program
    Eliezer Masliah, Director, Division of Neuroscience, NIA/NIH
  • AD/ADRD Research Milestones Progress Report
    Richard Hodes, Director, NIA/NIH

8:30am - 9:30am

Plenary Talks:

  • The Role of Public Advocacy in the Global Fight Against Dementia
    Maria Carrillo, Alzheimer's Association
  • Biomedical Research in the Era of Precision Medicine: The All of US Initiative
    Joni Rutter, NIH
  • The Future is Now: Deconstructing Disease Complexity to Enable Precision Medicine for AD
    Eric Schadt, Icahn Institute at Mount Sinai

9:30am – 11:45am

SESSION ONE
Novel Mechanistic Insights into the Complex Biology and Heterogeneity of AD

Chairs: Nilufer Ertekin-Taner (Mayo Clinic) and Robert Bell (Pfizer)

Speakers:

  • Rediscovering Myelin: From Genetics to Molecular Mechanisms
    Nilufer Ertekin-Taner, Mayo Clinic
  • Novel Insights in the Neuroimmune Etiology of AD
    Joel Dudley, Icahn Institute at Mount Sinai
  • Autophagy: Common Mechanisms in Aging, Cancer and Alzheimer's
    Ana-Maria Cuervo, Albert Einstein College of Medicine
  • Structural Diversity of Pathogenic Proteins: Implications for Therapy Development
    Robert Tycko, NIDDK/NIH

Panelists:

  • Marco Colonna, Washington University
  • Carol Colton, Duke University
  • Elizabeth Bradshaw, Columbia University
  • Stuart Lipton, Scripps Research Institute
  • Lennart Mucke, Gladstone Institute, UCSF
  • Gabriela Chiosis, Memorial Sloan Kettering Cancer Center
  • Ben Wolozin, Boston University
  • Ben Readhead, ASU-Banner Health
  • Robert Bell, Pfizer

MODERATED DISCUSSION: 11:15am - 11:45am

11:45am - 12:45pm LUNCH

12:45pm - 2:45pm

SESSION TWO
Enabling Precision Medicine for AD

Chairs: David Bennett (Rush University) and Rima Kaddurah-Daouk (Duke University)

Speakers:

  • Integrative Metabolomics: From Target Discovery to Disease Sub-Classification
    Matthias Arnold, Institute for Bioinformatics and Systems Biology, Munich
  • Integrative Proteomics for Novel Target and Biomarker Discovery
    Nick Seyfried, Emory University
  • Translational Epidemiology of Diverse Cohorts
    Rachel Whitmer, University of California, San Francisco
  • AD Genetics in the Era of Precision Medicine: Signals from Global Collaborations
    Cornelia van Dujin, Erasmus University Rotterdam

Panelists:

  • Liana Apostolova, Indiana University
  • Nicole Schupf, Columbia University
  • Mariet Allen, Mayo Clinic
  • Nir Barzilai, Albert Einstein School of Medicine
  • Catherine Kaczorowski, Jackson Labs
  • Chris Gaiteri, Rush University
  • Sean Bendall, Stanford University

MODERATED DISCUSSION: 2:15pm - 2:45pm

2:45pm - 4:45pm

SESSION THREE
Translational Tools and Infrastructure for Predictive Drug Development

Chairs: David Collier (Eli Lilly) and Allan Levey (Emory University)

Speakers:

  • MODEL-AD Consortium: Infrastructure for Next-Gen Animal Models Development and Preclinical Efficacy Testing
    Greg Carter, Jackson Labs
  • Infrastructure and Recruitment for Next-Generation Clinical Trials
    Laurie Ryan, NIA/NIH
  • Deploying QSP Models for Precision Medicine – from Target Validation to Clinical Trial Design
    Cynthia J. Musante, Pfizer

Panelists:

  • Gerard Schellenberg, University of Pennsylvania
  • Nathan Price, Institute for Systems Biology
  • Joel Dudley, Icahn Institute at Mount Sinai
  • Opher Gileadi, Structural Genomics Consortium, Oxford
  • Jacob Hooker, Massachusetts General Hospital
  • Valentina Fossati, New York Stem Cell Foundation
  • Lorenzo Refolo, NIA/NIH

MODERATED DISCUSSION: 4:15pm – 4:45pm

4:45pm – 5:45pm

SESSION FOUR
Emerging Therapeutics Part I

Chairs: Kalpana Merchant (Chaperone Therapeutics) and Rachelle Doody (Roche)

Speakers:

  • Neurotrophic Modulators as a Therapeutic for AD
    Frank Longo, Stanford University
  • Neuro-regenerative Therapeutics for AD
    Robbie Brinton, University of Arizona
  • PDE4 inhibitors for MCI and AD
    Mark Gurney, Tetra Therapeutics
  • Reinvigorating the Industry Pipeline Through Precompetitive Partnerships
    David Collier, Eli Lilly

5:45pm Adjourn DAY 1

DAY 2

8:00am – 9:30am

SESSION FOUR
Emerging Therapeutics Part II

Chairs: Kalpana Merchant (Chaperone Therapeutics) and Rachelle Doody (Roche)

Panelists:

  • Mark Tuszynski, University of California, San Diego
  • Linda Van Eldik, University of Kentucky
  • Martin Watterson, Neurokine Therapeutics
  • Steven Wagner, University of California, San Diego
  • Michela Gallagher, AgeneBio
  • Rong Xu, Case Western Reserve University
  • Marina Sirota, University of California, San Francisco
  • Kalpana Merchant, Chaperone Therapeutics

MODERATED DISCUSSION: 8:45am – 9:30am

9:30am – 11:45am

SESSION FIVE
Understanding the Impact of the Environment to Advance Disease Prevention

Chairs: Laura Baker (Wake Forest University) and Chirag Patel (Harvard)

Speakers:

  • Translating Knowledge about Socioeconomic Risk Factors into Disease Prevention
    Jennifer Manly, Columbia University
  • The Circadian Etiology of AD
    Andrew Lim, University of Toronto
  • Measuring the Impact of Chemical Pollutants on the Brain Across the Lifespan
    Kelly Bakulski, University of Michigan
  • Multi-Modal Life-Style Interventions: What Non-Pharmacologic Interventions Tell Us About Disease Mechanisms
    Laura Baker, Wake Forest University

Panelists:

  • Mariana Figueiro, Rensselaer Polytechnic Institute
  • Andy Saykin, Indiana University
  • Rong Xu, Case Western Reserve University
  • Martha Clare Morris, Rush University
  • Aliza Wingo, Emory University
  • Noam Beckmann, Icahn Institute at Mount Sinai
  • Gaya Dowling, NIDA/NIH
  • Sumitra Muralidhar, U.S. Department of Veterans Affairs

MODERATED DISCUSSION: 11:15am – 11:45am

12:00pm – 1:00pm LUNCH

1:00pm – 3:15pm

SESSION SIX
Advances in Disease Monitoring, Assessment, and Care

Chairs: Rhoda Au (Boston University) and Magali Haas (Cohen Veterans Bioscience)

Speakers:

  • eHealth Tools to Quantify Brain Health across the Disease Trajectory
    Rhoda Au, Boston University
  • Digital Tools for Sleep Monitoring and Optimization
    Daniela Brunner, Early Signal
  • Revolutionizing In-home disease monitoring: the CART Initiative
    Jeff Kaye, Portland VA/Oregon Health & Science University
  • New Directions in Research on Care: Report from the AD Care Summit
    Laura Gitlin, Johns Hopkins University

Panelists:

  • Hiroko Dodge, Oregon Health & Science University/University of Michigan
  • Larsson Omberg, Sage Bionetworks
  • Dorothy Edwards, University of Wisconsin
  • Meryl Comer, Geoffrey Beene Foundation
  • Stephen Friend

MODERATED DISCUSSION: 2:45pm - 3:15pm

3:30pm – 5:30pm

SESSION SEVEN
Building an Open Science Research Ecosystem to Accelerate AD Therapy Development

Chairs: Lara Mangravite (Sage Bionetworks) and Eric Reiman (Banner Alzheimer's Institute)

Speakers:

  • Accelerating Reproducible and Translatable Discovery Research through Open Science
    Lara Mangravite, Sage Bionetworks
  • Why We Need Open Drug Discovery for AD
    Aled Edwards, Structural Genomics Consortium, Toronto
  • Liberating Clinical Trials Data to Enable Translational Learning
    Eric Reiman, Banner Alzheimer's Institute

Panelists:

  • Magali Haas, Cohen Veterans Bioscience
  • Richard Wilder, Gates Foundation
  • Stuart Buck, Arnold Foundation
  • Kevin Da Silva, Nature Neuroscience
  • Jessica Polka, ASAPbio
  • Giorgio Ascoli, George Mason University
  • Katja Brose, Chan-Zuckerberg Initiative
  • Scott Hayton, BGC3
  • Suzana Petanceska, NIA/NIH

MODERATED DISCUSSION: 4:45pm - 5:30pm

5:30pm MEETING ADJOURNS